Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025

Core Viewpoint - Idorsia Ltd held its Annual General Meeting (AGM) where shareholders overwhelmingly supported all proposals from the Board of Directors, indicating strong confidence in the company's future direction and leadership [1][2]. Corporate Governance - The AGM was attended by 166 shareholders representing 97,748,740 shares, which is 43.28% of the total outstanding shares [1]. - Shareholders approved the re-election of all Board members for a term until the conclusion of the AGM 2026, including Jean-Paul Clozel as Chairman [4]. - The company granted discharge to all members of the Board of Directors and the Executive Committee for the financial year 2024 [3]. Financial Performance - Shareholders approved the Annual Report 2024, the Consolidated Financial Statements 2024, and the Statutory Financial Statements 2024 [2]. - The appropriation of available earnings was approved, with the net loss for the year 2024 to be carried forward [3]. Compensation and Audit - The aggregate maximum amount of compensation for the Board of Directors and the Executive Committee for the upcoming terms was approved [5]. - Deloitte AG was re-elected as the statutory auditors for the financial year 2025 [6]. Company Vision and Strategy - Idorsia aims to challenge accepted medical paradigms and is focused on discovering, developing, and commercializing transformative medicines [8]. - The company is positioned to become a leading biopharmaceutical entity in Europe, leveraging its strong scientific core and promising development pipeline [9].